{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:39:29Z","timestamp":1790404769677,"version":"4.1.0"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,19]]},"DOI":"10.1093\/neuonc\/noy193","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T15:08:25Z","timestamp":1542035305000},"page":"306-313","source":"Crossref","is-referenced-by-count":88,"title":["Introduction of novel agents in the treatment of primary CNS lymphoma"],"prefix":"10.1093","volume":"21","author":[{"given":"Christian","family":"Grommes","sequence":"first","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[{"name":"Center for NeuroOncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han W","family":"Tun","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy T","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"issue":"5","key":"key\n\t\t\t\t2019021910522857700_CIT0001","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ajcp\/110.5.607","article-title":"Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d\u2019\u00e9tude des Leuc\u00e9nies et Autres Maladies du Sang (GOELAMS)","volume":"110","author":"Camilleri-Bro\u00ebt","year":"1998","journal-title":"Am J Clin Pathol"},{"issue":"6769","key":"key\n\t\t\t\t2019021910522857700_CIT0002","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0003","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0004","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"Camilleri-Bro\u00ebt","year":"2006","journal-title":"Blood"},{"issue":"9","key":"key\n\t\t\t\t2019021910522857700_CIT0005","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2008-09-175588","article-title":"Differential gene expression of central nervous system lymphoma response","volume":"113","author":"Tun","year":"2009","journal-title":"Blood"},{"issue":"2","key":"key\n\t\t\t\t2019021910522857700_CIT0007","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin Hematol"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0008","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/leu.2014.264","article-title":"The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing","volume":"29","author":"Vater","year":"2015","journal-title":"Leukemia"},{"issue":"17","key":"key\n\t\t\t\t2019021910522857700_CIT0009","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"key\n\t\t\t\t2019021910522857700_CIT0010","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","author":"Montesinos-Rongen","year":"2011","journal-title":"Acta Neuropathol"},{"issue":"6","key":"key\n\t\t\t\t2019021910522857700_CIT0011","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00401-012-1064-7","article-title":"Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma","volume":"124","author":"Montesinos-Rongen","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"19","key":"key\n\t\t\t\t2019021910522857700_CIT0012","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"key\n\t\t\t\t2019021910522857700_CIT0013","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.18632\/oncotarget.2080","article-title":"Mutational analysis of primary central nervous system lymphoma","volume":"5","author":"Bruno","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7332","key":"key\n\t\t\t\t2019021910522857700_CIT0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"7277","key":"key\n\t\t\t\t2019021910522857700_CIT0016","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"5870","key":"key\n\t\t\t\t2019021910522857700_CIT0017","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"12","key":"key\n\t\t\t\t2019021910522857700_CIT0018","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2008-12-194852","article-title":"TNFAIP3\/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas","volume":"114","author":"Honma","year":"2009","journal-title":"Blood"},{"issue":"11","key":"key\n\t\t\t\t2019021910522857700_CIT0019","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.18632\/oncotarget.653","article-title":"Recurrent targets of aberrant somatic hypermutation in lymphoma","volume":"3","author":"Khodabakhshi","year":"2012","journal-title":"Oncotarget"},{"key":"key\n\t\t\t\t2019021910522857700_CIT0020","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"issue":"2","key":"key\n\t\t\t\t2019021910522857700_CIT0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2399","article-title":"Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways","volume":"216","author":"Booman","year":"2008","journal-title":"J Pathol"},{"issue":"6","key":"key\n\t\t\t\t2019021910522857700_CIT0022","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic characterization of primary central nervous system lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0023","first-page":"1063","article-title":"BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma","volume":"9","author":"Braaten","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"key\n\t\t\t\t2019021910522857700_CIT0024","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0002-9440(10)65458-2","article-title":"Chromosomal imbalances in primary lymphomas of the central nervous system","volume":"155","author":"Rickert","year":"1999","journal-title":"Am J Pathol"},{"issue":"10","key":"key\n\t\t\t\t2019021910522857700_CIT0025","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/leu.2009.120","article-title":"Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma","volume":"23","author":"Schwindt","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1750-3639.2000.tb00244.x","article-title":"Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type","volume":"10","author":"Weber","year":"2000","journal-title":"Brain Pathol"},{"issue":"2","key":"key\n\t\t\t\t2019021910522857700_CIT0027","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00428-003-0836-9","article-title":"Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q","volume":"443","author":"Boonstra","year":"2003","journal-title":"Virchows Arch"},{"issue":"2","key":"key\n\t\t\t\t2019021910522857700_CIT0028","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0165-4608(00)00377-0","article-title":"Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry","volume":"125","author":"Harada","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"issue":"7","key":"key\n\t\t\t\t2019021910522857700_CIT0029","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"8","key":"key\n\t\t\t\t2019021910522857700_CIT0030","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/neuonc\/noy019","article-title":"Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma","volume":"20","author":"Bruno","year":"2018","journal-title":"Neuro Oncol"},{"issue":"6","key":"key\n\t\t\t\t2019021910522857700_CIT0031","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0002-9440(10)62487-X","article-title":"Absence of immunoglobulin class switch in primary lymphomas of the central nervous system","volume":"166","author":"Montesinos-Rongen","year":"2005","journal-title":"Am J Pathol"},{"issue":"5","key":"key\n\t\t\t\t2019021910522857700_CIT0032","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-05-1465","article-title":"Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation","volume":"103","author":"Montesinos-Rongen","year":"2004","journal-title":"Blood"},{"issue":"2","key":"key\n\t\t\t\t2019021910522857700_CIT0033","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1750-3639.1998.tb00152.x","article-title":"Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL","volume":"8","author":"Cobbers","year":"1998","journal-title":"Brain Pathol"},{"key":"key\n\t\t\t\t2019021910522857700_CIT0034","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-018-2940-3","article-title":"BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma","author":"Makino","year":"2018","journal-title":"J Neuro Oncol"},{"issue":"5","key":"key\n\t\t\t\t2019021910522857700_CIT0035","doi-asserted-by":"crossref","first-page":"e00178","DOI":"10.1002\/prp2.178","article-title":"Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax","volume":"3","author":"Ackler","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"17","key":"key\n\t\t\t\t2019021910522857700_CIT0036","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","author":"Plotkin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0037","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-014-1370-0","article-title":"Methotrexate re-challenge for recurrent primary central nervous system lymphoma","volume":"117","author":"Pentsova","year":"2014","journal-title":"J Neurooncol"},{"issue":"11","key":"key\n\t\t\t\t2019021910522857700_CIT0038","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","article-title":"Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma","volume":"69","author":"Hottinger","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"key\n\t\t\t\t2019021910522857700_CIT0039","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2005.01.161","article-title":"Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma","volume":"23","author":"Nguyen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"key\n\t\t\t\t2019021910522857700_CIT0040","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0041","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12185-013-1403-z","article-title":"Treatment outcome of relapsed\/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation","volume":"98","author":"Choi","year":"2013","journal-title":"Int J Hematol"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0042","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2037","article-title":"Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy","volume":"31","author":"Mappa","year":"2013","journal-title":"Hematol Oncol"},{"issue":"15","key":"key\n\t\t\t\t2019021910522857700_CIT0043","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","article-title":"Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle Osseuse-Th\u00e9rapie Cellulaire","volume":"26","author":"Soussain","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"key\n\t\t\t\t2019021910522857700_CIT0044","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/neuonc\/nos207","article-title":"Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center","volume":"14","author":"Welch","year":"2012","journal-title":"Neuro Oncol"},{"issue":"15","key":"key\n\t\t\t\t2019021910522857700_CIT0045","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/cncr.26709","article-title":"Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma","volume":"118","author":"Raizer","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"key\n\t\t\t\t2019021910522857700_CIT0046","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","article-title":"Prospective trial on topotecan salvage therapy in primary CNS lymphoma","volume":"17","author":"Fischer","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"key\n\t\t\t\t2019021910522857700_CIT0047","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","article-title":"Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma","volume":"86","author":"Voloschin","year":"2008","journal-title":"J Neurooncol"},{"issue":"6","key":"key\n\t\t\t\t2019021910522857700_CIT0048","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","author":"Reni","year":"2007","journal-title":"Br J Cancer"},{"issue":"10","key":"key\n\t\t\t\t2019021910522857700_CIT0049","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/10428194.2012.698736","article-title":"Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma","volume":"54","author":"Nayak","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"key\n\t\t\t\t2019021910522857700_CIT0051","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1212\/WNL.54.8.1707","article-title":"PCV salvage chemotherapy for recurrent primary CNS lymphoma","volume":"54","author":"Herrlinger","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"key\n\t\t\t\t2019021910522857700_CIT0052","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1600-0609.2003.00045.x","article-title":"Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma","volume":"70","author":"Arellano-Rodrigo","year":"2003","journal-title":"Eur J Haematol"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0053","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.20339","article-title":"Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas","volume":"101","author":"Wong","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"key\n\t\t\t\t2019021910522857700_CIT0054","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","article-title":"Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide","volume":"63","author":"Enting","year":"2004","journal-title":"Neurology"},{"issue":"11","key":"key\n\t\t\t\t2019021910522857700_CIT0055","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jocn.2012.04.001","article-title":"A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide","volume":"19","author":"Wong","year":"2012","journal-title":"J Clin Neurosci"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0056","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11060-013-1196-1","article-title":"Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma","volume":"115","author":"Zhang","year":"2013","journal-title":"J neuro-oncol"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0057","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-014-1411-8","article-title":"Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series","volume":"118","author":"Chamberlain","year":"2014","journal-title":"J neuro-oncol"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0058","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0059","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11060-015-1994-8","article-title":"High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma","volume":"126","author":"Chamberlain","year":"2016","journal-title":"J neuro-oncol"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.0000000000003420","article-title":"Ibrutinib Monotherapy in Relapsed\/Refractory Cns Lymphoma: A Retrospective Case Series","volume":"88","author":"Chamoun","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"key\n\t\t\t\t2019021910522857700_CIT0061","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood-2012-07-440974","article-title":"Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"issue":"15","key":"key\n\t\t\t\t2019021910522857700_CIT0062","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II trial of temsirolimus for relapsed\/refractory primary CNS lymphoma","volume":"34","author":"Korfel","year":"2016","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019021910522857700_CIT0063","article-title":"Phase II study of single agent buparlisib in recurrent\/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)","volume":"27(suppl 6):335","author":"Grommes","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"key\n\t\t\t\t2019021910522857700_CIT0064","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019021910522857700_CIT0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.784.784","article-title":"Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC Network","volume":"128","author":"Choquet","year":"2016","journal-title":"Blood"},{"issue":"6","key":"key\n\t\t\t\t2019021910522857700_CIT0066","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"8","key":"key\n\t\t\t\t2019021910522857700_CIT0067","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0068","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00277-012-1569-0","article-title":"Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study","volume":"92","author":"Oliva","year":"2013","journal-title":"Ann Hematol"},{"issue":"1-2","key":"key\n\t\t\t\t2019021910522857700_CIT0069","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"issue":"13","key":"key\n\t\t\t\t2019021910522857700_CIT0070","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"key":"key\n\t\t\t\t2019021910522857700_CIT0071","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase I study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreo-retinal lymphoma","author":"Tun","year":"2018","journal-title":"Blood"},{"issue":"8","key":"key\n\t\t\t\t2019021910522857700_CIT0072","doi-asserted-by":"crossref","first-page":"e71754","DOI":"10.1371\/journal.pone.0071754","article-title":"Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"key\n\t\t\t\t2019021910522857700_CIT0073","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"key\n\t\t\t\t2019021910522857700_CIT0074","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/asheducation-2017.1.556","article-title":"Biology of CNS lymphoma and the potential of novel agents","volume":"2017","author":"Rubenstein","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"key\n\t\t\t\t2019021910522857700_CIT0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.785.785","article-title":"Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a \u201cproof of concept\u201d phase II study of the French LOC network","volume":"128","author":"Ghesquieres","year":"2016","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019021910522857700_CIT0076","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15009","article-title":"Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model","author":"Qiu","year":"2018;183(4):674\u2013678","journal-title":"Br J Haematol"},{"issue":"23","key":"key\n\t\t\t\t2019021910522857700_CIT0077","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"8","key":"key\n\t\t\t\t2019021910522857700_CIT0078","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/21\/3\/306\/27886440\/noy193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T15:24:21Z","timestamp":1572621861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/21\/3\/306\/5180478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":78,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,13]]},"published-print":{"date-parts":[[2019,2,19]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noy193","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,11,13]]}}}